2004
DOI: 10.1016/j.ahj.2004.02.014
|View full text |Cite
|
Sign up to set email alerts
|

Clinical trial–derived risk model may not generalize to real-world patients with acute coronary syndrome

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

2
38
0
2

Year Published

2007
2007
2021
2021

Publication Types

Select...
8
1

Relationship

2
7

Authors

Journals

citations
Cited by 84 publications
(42 citation statements)
references
References 29 publications
2
38
0
2
Order By: Relevance
“…97 For instance, a risk model derived from a more heterogeneous case mix provided better calibration in risk assessment across the spectrum of acute coronary syndromes than another model derived using a clinical trial population, although both models showed similar discriminatory ability. 98 …”
Section: Model Validationmentioning
confidence: 99%
“…97 For instance, a risk model derived from a more heterogeneous case mix provided better calibration in risk assessment across the spectrum of acute coronary syndromes than another model derived using a clinical trial population, although both models showed similar discriminatory ability. 98 …”
Section: Model Validationmentioning
confidence: 99%
“…Our data underscore the importance of risk model validation in an appropriate target population rather than a clinical trial population to establish its generalizability before integration into clinical practice. 29 So how can we best expedite management of the low to intermediate risk patient who presents to the ED with chest pain? Patients who present with chest pain that can be attributed to a non-cardiac cause should require no further cardiac testing.…”
Section: Discussionmentioning
confidence: 99%
“…363 Clinical registries address some of the selection bias and are valuable resources for comparison and for assessing trends in treatment. [363][364][365][366][367] The finding of similarly high PCI rates in an unselected (SWEDEHEART/RIKS-HIA) and a selected (ACTION) registry makes the differences seen in other aspects of NSTEMI care more informative. It suggests that US procedure rates are not being driven by fee for service and that Sweden's increased emphasis on system-wide quality improvement is bearing fruit.…”
Section: Discussionmentioning
confidence: 99%